Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

被引:202
作者
Petit, T
Wilt, M
Velten, M
Millon, R
Rodier, JF
Borel, C
Mors, R
Haegelé, P
Eber, M
Ghnassia, JP
机构
[1] Ctr Lutte Contre Canc Paul Strauss, Dept Med Oncol, F-67065 Strasbourg, France
[2] Ctr Lutte Contre Canc Paul Strauss, Dept Pathol, Strasbourg, France
[3] Ctr Lutte Contre Canc Paul Strauss, Dept Biostat, Strasbourg, France
[4] Ctr Lutte Contre Canc Paul Strauss, Dept Mol Biol, Strasbourg, France
[5] Ctr Lutte Contre Canc Paul Strauss, Dept Surg Oncol, Strasbourg, France
关键词
breast cancer; neoadjuvant chemotherapy; predictive factors;
D O I
10.1016/S0959-8049(03)00675-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) hormonal receptor (HR) status; (3) tumour cell proliferation evaluated by Ki-67 staining, (4) HER-2 and topoisomerase 11 alpha (TopoIIalpha) expression evaluated by immunohistochemistry (IHC), (5) HER-2 and TopoIIalpha amplification evaluated by real-time polymerase chain reaction (PCR). 119 patients with operable breast cancer were treated with six cycles of FEC (100 5-fluorouracil (5-FU) 500 mg/m(2), Epirubicin 100 mg/m(2), Cyclophosphamide 500 mg/m(2)). Tumour response was assessed clinically and by computed tomography (CT) scan, then by pathological assessment. The clinical overall response (OR) was 80%, with 19% of complete responders (CR). The radiological OR was 71%, with 16% of CR. A pathological CR was demonstrated in 13% of the patients according to the Sataloff classification. In the multivariate analysis, the absence of HR expression and Ki-67 greater than or equal to 20% were predictive for a clinical CR. A high tumour grade was predictive for a pathological CR. Overexpression or amplification of HER2 or Topollcalpha were not predictive of response. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 40 条
[1]   Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy [J].
Aas, T ;
Geisler, S ;
Eide, GE ;
Haugen, DF ;
Varhaug, JE ;
Bassoe, AM ;
Thorsen, T ;
Berntsen, H ;
Borresen-Dale, AL ;
Akslen, LA ;
Lonning, PE .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (04) :438-446
[2]  
Amat S, 2002, INT J ONCOL, V20, P791
[3]   INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE [J].
CHEVALLIER, B ;
ROCHE, H ;
OLIVIER, JP ;
CHOLLET, P ;
HURTELOUP, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03) :223-228
[4]   Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer [J].
Chollet, P ;
Amat, S ;
Cure, H ;
de Latour, M ;
Le Bouedec, G ;
Mouret-Reynier, MA ;
Ferriere, JP ;
Achard, JL ;
Dauplat, J ;
Penault-Llorca, F .
BRITISH JOURNAL OF CANCER, 2002, 86 (07) :1041-1046
[5]   Prediction of response to primary chemotherapy for operable breast cancer [J].
Colleoni, M ;
Orvieto, E ;
Nolé, F ;
Orlando, L ;
Minchella, I ;
Viale, G ;
Peruzzotti, G ;
Robertson, C ;
Noberasco, C ;
Galimberti, V ;
Sacchini, V ;
Veronesi, P ;
Zurrida, S ;
Orecchia, R ;
Goldhirsch, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) :574-579
[6]  
Coon JS, 2002, CLIN CANCER RES, V8, P1061
[7]   Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma [J].
Couturier, J ;
Vincent-Salomon, A ;
Nicolas, A ;
Beuzeboc, P ;
Mouret, E ;
Zafrani, B ;
Sastre-Garau, X .
MODERN PATHOLOGY, 2000, 13 (11) :1238-1243
[8]  
Daidone MG, 1999, INT J CANCER, V84, P580, DOI 10.1002/(SICI)1097-0215(19991222)84:6<580::AID-IJC7>3.0.CO
[9]  
2-W
[10]   HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide [J].
Di Leo, A ;
Larsimont, D ;
Gancberg, D ;
Jarvinen, T ;
Beauduin, M ;
Vindevoghel, A ;
Michel, J ;
Focan, C ;
Ries, F ;
Gobert, P ;
Closon-Dejardin, MT ;
Dolci, S ;
Rouas, G ;
Paesmans, M ;
Lobelle, JP ;
Isola, J ;
Piccart, MJ .
ANNALS OF ONCOLOGY, 2001, 12 (08) :1081-1089